Nemera

What they make

1 input Nemera supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Did you know2024

  Nemera's precision nasal spray pump platform (Topline) — designed to deliver a metered, consistent pharmaceutical dose per actuation to the nasal mucosa — is engineering-wise nearly identical to the consumer nasal spray pump used in Flonase, Nasacort, and Afrin (oxymetazoline). The difference between Nemera's pharmaceutical device and the consumer OTC pump is regulatory qualification (FDA 505(b)(2) or NDA combination product filing) and quality documentation, not mechanical engineering. The same injection-molded polymer pump technology that delivers intranasal esketamine (Spravato, for treatment-resistant depression) or naloxone (Narcan nasal, for opioid overdose reversal) shares technical specification ancestors with the OTC decongestant spray sold at every pharmacy checkout. When Narcan intranasal (an emergency life-saving drug) faced supply shortages in 2022-2023, the polymer nasal device supply chain that underpins it and the consumer OTC nasal spray supply chain were drawing from the same tier of precision pump manufacturers and polymer molders.

  Nemera ↗

• Concentration2023

  The independent (non-pharma-captive) drug delivery device market — the tier of companies that make the plastic and metal housings, pumps, and actuators that pharmaceutical companies fill with their drugs — is served by a surprisingly small number of multinationals: AptarGroup (US, formerly Calmar), Gerresheimer (Germany), Berry Global Pharma (US), Nemera (France/US), and a handful of others. Every metered nasal spray (allergy, migraine, opioid reversal), every pMDI actuator housing, and every auto-injector pen body for a biologic drug passes through one of these companies' injection molding facilities before the pharma company fills it with an active ingredient. Pharma companies typically qualify one or two device suppliers per product under strict regulatory requirements, creating single-source device-to-drug registration chains that are expensive and slow to change. The device supply chain for branded pharmaceuticals is therefore more concentrated and less substitutable than it appears from the outside, with device suppliers holding disproportionate influence over pharma company launch timelines when devices are in shortage.

  Drug Delivery Business News ↗

• Origin2024

  Nemera was created in 2015 when Apax Partners, a private equity firm, acquired and rebranded the combination of two drug delivery device companies: Alliance Medical Products (a US nasal and inhalation device maker) and La Verpillière-based Drug Delivery International (DDI, a French ophthalmic and inhalation device manufacturer). The combination created a single platform serving pharma companies across all non-injectable drug delivery routes. La Verpillière, near Lyon in France's Isère department, sits at the center of France's polymer processing industry — the Auvergne-Rhône-Alpes region hosts a dense network of injection molding, plastics engineering, and precision mechanical component manufacturers whose workforce and industrial culture were foundational to Nemera's manufacturing capability. The PE-backed rollup strategy reflected the recognition that pharma companies increasingly want a single device partner across inhaler, nasal, ophthalmic, and parenteral delivery — requiring exactly the kind of multi-modal platform Nemera assembled.

  Nemera ↗